Looking at imeglimin literature, I was currently focusing on the effect on mitochondria, and a few papers were interesting enough to share here in a batch (with brief commentary from me).
There has been talk here about imeglimin vs metformin in regard to exercise, and a question about the possibility that imeglimin might be similarly suboptimal in the context of exercise. It seems not. In fact, there might be synergies between imeglimin and exercise - at least resistance exercise (free article).
Combination of imeglimin and resistance exercise improves mitochondrial function and glucose metabolism in skeletal muscles
“These findings suggest that the combination of imeglimin and RT [Resistance Training] is a promising therapeutic approach to enhance mitochondrial function and glucose metabolic capacity.”
There have been suggestions that some drugs that were used in T2DM were actually beneficial for CV health, such as SGLT2i. Well, it looks like perhaps imeglimin might join the club, insofar as it might mitigate atherosclerosis - who knew!
Molecular mechanism for pancreatic β-cell dysfunction and atherosclerosis
“Recently we have reported that imeglimin exerts beneficial effects on mitochondria morphology in β-cells and/or number and quality of insulin granules. In addition, we have reported that imeglimin shows favorable effects against the development of atherosclerosis independently of glycemic and lipid control.”
That part about the effect on atherosclerosis was independent of glycemic and lipid control is very important, because it tells us that this effect is not solely due to imeglimin being an anti-diabetic agent, and also because it can be used as an addition to LLT (statins, ezetimibe etc.), and the effects on atherosclerosis should therefore stack.
How does imeglimin work in beta cells? Overview.
Current understanding of imeglimin action on pancreatic β‐cells: Involvement of mitochondria and endoplasmic reticulum homeostasis
A big part of fighting aging is centered around the inflammatory process that is downstream from LPS propagation. It looks like imeglimin might be helpful here (free article).
Imeglimin attenuates NLRP3 inflammasome activation by restoring mitochondrial functions in macrophages
“We demonstrated for the first time that imeglimin reduces LPS-induced NLRP3 inflammasome activation by inhibiting mPTP opening in THP-1 macrophages. These results suggest that imeglimin could be a promising new anti-inflammatory agent for treating diabetic complications.”
The next paper speaks for itself - mitochondrial ROS is a fundamental driver of aging, so it’s nice to see imeglimin might be helpful here (free article).
Suppressing Mitochondrial ROS Production is Beneficial in Multiple Preclinical Models of Human Disease
Finally, the last paper is just a case report, but I liked it because it used three classes of drugs, which many of us have an interest in: SGLT2i, ARB and glimin. As a small additional factor, the ARB in question is olmesartan which I have increasing interest in.
Mitochondrial Nephropathy With m.5538G>A Mutation Within the tRNA-Trp Region Assessed by Mitochondrial Function Analysis: A Case Report